XBiotech wins 2nd fast-track status for therapeutic antibody

01/8/2013 | American City Business Journals

The FDA granted a second fast-track designation to XBiotech USA's therapeutic monoclonal antibody MABp1 as a treatment for restenosis and vascular disease. The drug previously received a fast-track status for advanced cancer with related cachexia. XBiotech is seeking multiple approvals to create a new treatment paradigm -- that inhibiting chronic inflammation can address multiple diseases.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN